Profile - To The Moon

Joyce_c

Posts · 13Posts · 13
Following · 0Following · 0
Followers · 0Followers · 0

- Joyce_cJoyce_c
  ·2021-03-18
  Ok
  3 Biotech Stocks to Avoid Right Now
  Here's why these attention-grabbing stocks could be toxic to your portfolio. Did you know that newb
  3 Biotech Stocks to Avoid Right Now
  251 Comment
  5
  Share
  Report
- Joyce_cJoyce_c
  ·2021-03-16
  $Ebang International Holdings Inc.(EBON)$Oh no
  890 1
  3
  Share
  Report
- Joyce_cJoyce_c
  ·2021-03-12
  $Super League Gaming Inc.(SLGG)$New
  128 Comment
  2
  Share
  Report
- Joyce_cJoyce_c
  ·2021-03-12
  $Super League Gaming Inc.(SLGG)$Nice
  233 Comment
  4
  Share
  Report
- Joyce_cJoyce_c
  ·2021-03-07
  Nice
  Sorry, this post has been deleted
  247 Comment
  2
  Share
  Report
- Joyce_cJoyce_c
  ·2021-03-04
  $Tesla Motors(TSLA)$Oh no
  204 Comment
  4
  Share
  Report
- Joyce_cJoyce_c
  ·2021-03-02
  Nice
  10-year Treasury yield continues to retreat from last week's high
  KEY POINTSInvestors on Tuesday will be keeping a close watch on comments made by both Securities and
  10-year Treasury yield continues to retreat from last week's high
  233 2
  3
  Share
  Report
- Joyce_cJoyce_c
  ·2021-03-02
  Nice
  Beyond Meat Prepares for a High-Growth Phase
  I’ve been a Beyond Meat (BYND) fan for a while now, despite the crazy way the pandemic has moved its
  Beyond Meat Prepares for a High-Growth Phase
  176 Comment
  7
  Share
  Report
- Joyce_cJoyce_c
  ·2021-03-02
  Good
  Sorry, this post has been deleted
  87 Comment
  4
  Share
  Report
- Joyce_cJoyce_c
  ·2021-03-01
  $Zomedica Pharmaceuticals Corp.(ZOM)$good?
  98 Comment
  7
  Share
  Report
No following yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3572419380684882","uuid":"3572419380684882","gmtCreate":1609325357385,"gmtModify":1614306760159,"name":"Joyce_c","pinyin":"joycecjoycec","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/faf0f288ddf8de4ed8f2127882064d27","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":8,"tweetSize":13,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":327185391,"gmtCreate":1616070327413,"gmtModify":1704790490045,"author":{"id":"3572419380684882","authorId":"3572419380684882","name":"Joyce_c","avatar":"https://static.tigerbbs.com/faf0f288ddf8de4ed8f2127882064d27","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572419380684882","authorIdStr":"3572419380684882"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/327185391","repostId":"1142227040","repostType":4,"repost":{"id":"1142227040","pubTimestamp":1616070253,"share":"https://ttm.financial/m/news/1142227040?lang=&edition=fundamental","pubTime":"2021-03-18 20:24","market":"us","language":"en","title":"3 Biotech Stocks to Avoid Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1142227040","media":"Motley Fool","summary":"Here's why these attention-grabbing stocks could be toxic to your portfolio.\n\nDid you know that newb","content":"<blockquote>\n <b>Here's why these attention-grabbing stocks could be toxic to your portfolio.</b>\n</blockquote>\n<p>Did you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this space to choose from, it's a little surprising that some of the most popular companies right now haven't had much success when it comes to drug development.</p>\n<p>Every business has a story to tell, and plenty of investors like what they've been hearing from these three. Before following the crowd, though, you should know that there are potholes along these companies' paths to success.</p>\n<p><img src=\"https://static.tigerbbs.com/98c795e31990a6c24ab59592b22abd7a\" tg-width=\"796\" tg-height=\"207\"><b>1. Cassava Sciences</b></p>\n<p>This company's developing a potential new Alzheimer's disease drug called simufilam. In the U.S., 1 in 9 people over the age of 65 have Alzheimer's disease, but there still aren't any available treatments for this progressive and ultimately fatal disease. As the first, simufilam could become one of the top-selling drugs of its time.</p>\n<p>Following a successful phase 2 trial, Cassava Sciences told investors the Food and Drug Administration (FDA) gave the green light for a pair of phase 3 trials slated to begin in the second half of the year. If simufilam succeeds at both, shares of this biotech could explode higher.</p>\n<p>Unfortunately, Cassava Sciences has been developing simufilam for over a decade and it still doesn't have any evidence from a randomized controlled trial that simufilam works as intended.</p>\n<p>The company included a placebo group in a smallphase 2study that read out last year, but simufilam failed to reduce signs of inflammation that show up in fluid that bathes the brain. Investigators also gave Alzheimer's disease patients cognitive tests to see if simufilam actually made a difference, but they couldn't measure an improvement.</p>\n<p><b>2. Ocugen</b></p>\n<p>Shares of this clinical-stage drugmaker have been soaring in response to good news for a COVID-19 vaccine called Covaxin. The vaccine's developer, Bharat Biotech, is a well-established vaccine manufacturer headquartered in India.</p>\n<p>Bharat Biotech has hired Ocugen to co-develop Covaxin for the U.S. market, and it looks like a winner. In a phase 3 study with over 25,000 volunteers, Covaxin was about 81% effective at preventing COVID-19 infections in India.</p>\n<p>Before buying any Ocugen shares, you should know that the FDA wasn't willing to consider emergency use authorization requests without data from lots of U.S. trial volunteers when there were zero COVID-19vaccines available. Now that the agency has already authorized three safe and effective options, there's zero chance that Ocugen will sell Covaxin in the U.S. without a new phase 3 trial.</p>\n<p><b>3. Rubius Therapeutics</b></p>\n<p>This clinical-stage biotech is developing new cancer therapies made from a line of red blood cells that can be taken off a shelf and administered as soon as they're prescribed. Shares of Rubius have soared this year, thanks to some tumor shrinkage observed in an early-stage study with a variety of cancer patients taking its lead candidate RTX-240.</p>\n<p>In an interim assessment of an ascending-dosage trial that had data from 16 volunteers available, two of the patients have responded well to RTX-240 treatment. While this looks like a pretty good result for an interim analysis of an early trial, it's probably too early for anyone at Rubius to begin celebrating. That's because the only confirmed tumor shrinkage presented so far occurred for a patient treated with the lowest dosage tested.</p>\n<p>Rubius Therapeutics' red blood cells are engineered to excite and enlist different types of white blood cells to take action against tumors. The company was able to show expansion of natural killer cells and T-cells for eight patients earlier this year. Unfortunately, the company hasn't been able to show RTX-240 expanded these tumor-fighting cells for the patients who responded.</p>\n<p><b>Looking forward</b></p>\n<p>All of these companies have huge market valuations right now that could come crashing down if their lead programs can't deliver. That's because there's nearly nothing for them to fall back on.</p>\n<p>Ocugen doesn't have any potential new drugs in clinical trials right now, and it's going to be a long time before we know if the gene therapies it intends to develop have a shot at success. Cassava Sciences has a potential new test for biomarkers that could indicate Alzheimer's disease, but simufilam is the only clinical-stage new drug candidate in its pipeline.</p>\n<p>Rubius Therapeutics is developing a platform of red-blood-cell-based treatments, and the company already has a second candidate cleared by the FDA to begin clinical trials. If any of these companies has a fallback if its lead candidate doesn't work out, it's Rubius. That said, it's still way too risky to consider putting in your portfolio at the moment.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotech Stocks to Avoid Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotech Stocks to Avoid Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-18 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/18/3-biotech-stocks-to-avoid-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here's why these attention-grabbing stocks could be toxic to your portfolio.\n\nDid you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/18/3-biotech-stocks-to-avoid-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc","OCGN":"Ocugen","RUBY":"Rubius Therapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/03/18/3-biotech-stocks-to-avoid-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142227040","content_text":"Here's why these attention-grabbing stocks could be toxic to your portfolio.\n\nDid you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this space to choose from, it's a little surprising that some of the most popular companies right now haven't had much success when it comes to drug development.\nEvery business has a story to tell, and plenty of investors like what they've been hearing from these three. Before following the crowd, though, you should know that there are potholes along these companies' paths to success.\n1. Cassava Sciences\nThis company's developing a potential new Alzheimer's disease drug called simufilam. In the U.S., 1 in 9 people over the age of 65 have Alzheimer's disease, but there still aren't any available treatments for this progressive and ultimately fatal disease. As the first, simufilam could become one of the top-selling drugs of its time.\nFollowing a successful phase 2 trial, Cassava Sciences told investors the Food and Drug Administration (FDA) gave the green light for a pair of phase 3 trials slated to begin in the second half of the year. If simufilam succeeds at both, shares of this biotech could explode higher.\nUnfortunately, Cassava Sciences has been developing simufilam for over a decade and it still doesn't have any evidence from a randomized controlled trial that simufilam works as intended.\nThe company included a placebo group in a smallphase 2study that read out last year, but simufilam failed to reduce signs of inflammation that show up in fluid that bathes the brain. Investigators also gave Alzheimer's disease patients cognitive tests to see if simufilam actually made a difference, but they couldn't measure an improvement.\n2. Ocugen\nShares of this clinical-stage drugmaker have been soaring in response to good news for a COVID-19 vaccine called Covaxin. The vaccine's developer, Bharat Biotech, is a well-established vaccine manufacturer headquartered in India.\nBharat Biotech has hired Ocugen to co-develop Covaxin for the U.S. market, and it looks like a winner. In a phase 3 study with over 25,000 volunteers, Covaxin was about 81% effective at preventing COVID-19 infections in India.\nBefore buying any Ocugen shares, you should know that the FDA wasn't willing to consider emergency use authorization requests without data from lots of U.S. trial volunteers when there were zero COVID-19vaccines available. Now that the agency has already authorized three safe and effective options, there's zero chance that Ocugen will sell Covaxin in the U.S. without a new phase 3 trial.\n3. Rubius Therapeutics\nThis clinical-stage biotech is developing new cancer therapies made from a line of red blood cells that can be taken off a shelf and administered as soon as they're prescribed. Shares of Rubius have soared this year, thanks to some tumor shrinkage observed in an early-stage study with a variety of cancer patients taking its lead candidate RTX-240.\nIn an interim assessment of an ascending-dosage trial that had data from 16 volunteers available, two of the patients have responded well to RTX-240 treatment. While this looks like a pretty good result for an interim analysis of an early trial, it's probably too early for anyone at Rubius to begin celebrating. That's because the only confirmed tumor shrinkage presented so far occurred for a patient treated with the lowest dosage tested.\nRubius Therapeutics' red blood cells are engineered to excite and enlist different types of white blood cells to take action against tumors. The company was able to show expansion of natural killer cells and T-cells for eight patients earlier this year. Unfortunately, the company hasn't been able to show RTX-240 expanded these tumor-fighting cells for the patients who responded.\nLooking forward\nAll of these companies have huge market valuations right now that could come crashing down if their lead programs can't deliver. That's because there's nearly nothing for them to fall back on.\nOcugen doesn't have any potential new drugs in clinical trials right now, and it's going to be a long time before we know if the gene therapies it intends to develop have a shot at success. Cassava Sciences has a potential new test for biomarkers that could indicate Alzheimer's disease, but simufilam is the only clinical-stage new drug candidate in its pipeline.\nRubius Therapeutics is developing a platform of red-blood-cell-based treatments, and the company already has a second candidate cleared by the FDA to begin clinical trials. If any of these companies has a fallback if its lead candidate doesn't work out, it's Rubius. That said, it's still way too risky to consider putting in your portfolio at the moment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":251,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":325234874,"gmtCreate":1615901732898,"gmtModify":1704788175355,"author":{"id":"3572419380684882","authorId":"3572419380684882","name":"Joyce_c","avatar":"https://static.tigerbbs.com/faf0f288ddf8de4ed8f2127882064d27","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572419380684882","authorIdStr":"3572419380684882"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EBON\">$Ebang International Holdings Inc.(EBON)$</a>Oh no","listText":"<a href=\"https://laohu8.com/S/EBON\">$Ebang International Holdings Inc.(EBON)$</a>Oh no","text":"$Ebang International Holdings Inc.(EBON)$Oh no","images":[{"img":"https://static.tigerbbs.com/1cb175c60e55e5afbfb523d0ecb69cd3","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/325234874","isVote":1,"tweetType":1,"viewCount":890,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":328739828,"gmtCreate":1615558732864,"gmtModify":1704784534678,"author":{"id":"3572419380684882","authorId":"3572419380684882","name":"Joyce_c","avatar":"https://static.tigerbbs.com/faf0f288ddf8de4ed8f2127882064d27","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572419380684882","authorIdStr":"3572419380684882"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SLGG\">$Super League Gaming Inc.(SLGG)$</a>New","listText":"<a href=\"https://laohu8.com/S/SLGG\">$Super League Gaming Inc.(SLGG)$</a>New","text":"$Super League Gaming Inc.(SLGG)$New","images":[{"img":"https://static.tigerbbs.com/96b312ed746fbc6033863fbfa769bc6c","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328739828","isVote":1,"tweetType":1,"viewCount":128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":328730497,"gmtCreate":1615558714919,"gmtModify":1704784534027,"author":{"id":"3572419380684882","authorId":"3572419380684882","name":"Joyce_c","avatar":"https://static.tigerbbs.com/faf0f288ddf8de4ed8f2127882064d27","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572419380684882","authorIdStr":"3572419380684882"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SLGG\">$Super League Gaming Inc.(SLGG)$</a>Nice","listText":"<a href=\"https://laohu8.com/S/SLGG\">$Super League Gaming Inc.(SLGG)$</a>Nice","text":"$Super League Gaming Inc.(SLGG)$Nice","images":[{"img":"https://static.tigerbbs.com/0a4fc92f594e9d583fc2b801f703aa59","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328730497","isVote":1,"tweetType":1,"viewCount":233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":320262014,"gmtCreate":1615119060938,"gmtModify":1704778769499,"author":{"id":"3572419380684882","authorId":"3572419380684882","name":"Joyce_c","avatar":"https://static.tigerbbs.com/faf0f288ddf8de4ed8f2127882064d27","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572419380684882","authorIdStr":"3572419380684882"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/320262014","repostId":"1161529893","repostType":4,"isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":364812129,"gmtCreate":1614833113161,"gmtModify":1704775795281,"author":{"id":"3572419380684882","authorId":"3572419380684882","name":"Joyce_c","avatar":"https://static.tigerbbs.com/faf0f288ddf8de4ed8f2127882064d27","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572419380684882","authorIdStr":"3572419380684882"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Oh no","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>Oh no","text":"$Tesla Motors(TSLA)$Oh no","images":[{"img":"https://static.tigerbbs.com/18355490d13896c2d6b2b02d953d0c29","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/364812129","isVote":1,"tweetType":1,"viewCount":204,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":365079607,"gmtCreate":1614684723209,"gmtModify":1704773979270,"author":{"id":"3572419380684882","authorId":"3572419380684882","name":"Joyce_c","avatar":"https://static.tigerbbs.com/faf0f288ddf8de4ed8f2127882064d27","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572419380684882","authorIdStr":"3572419380684882"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/365079607","repostId":"1197656800","repostType":4,"repost":{"id":"1197656800","pubTimestamp":1614676908,"share":"https://ttm.financial/m/news/1197656800?lang=&edition=fundamental","pubTime":"2021-03-02 17:21","market":"us","language":"en","title":"10-year Treasury yield continues to retreat from last week's high","url":"https://stock-news.laohu8.com/highlight/detail?id=1197656800","media":"cnbc","summary":"KEY POINTSInvestors on Tuesday will be keeping a close watch on comments made by both Securities and","content":"<div>\n<p>KEY POINTSInvestors on Tuesday will be keeping a close watch on comments made by both Securities and Exchange Commission Chair nominee Gary Gensler and Federal Reserve Governor Lael Brainard.Gensler ...</p>\n\n<a href=\"https://www.cnbc.com/2021/03/02/us-bonds-treasury-yields-continue-to-retreat-from-last-weeks-highs.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10-year Treasury yield continues to retreat from last week's high</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10-year Treasury yield continues to retreat from last week's high\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-02 17:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/03/02/us-bonds-treasury-yields-continue-to-retreat-from-last-weeks-highs.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTSInvestors on Tuesday will be keeping a close watch on comments made by both Securities and Exchange Commission Chair nominee Gary Gensler and Federal Reserve Governor Lael Brainard.Gensler ...</p>\n\n<a href=\"https://www.cnbc.com/2021/03/02/us-bonds-treasury-yields-continue-to-retreat-from-last-weeks-highs.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.cnbc.com/2021/03/02/us-bonds-treasury-yields-continue-to-retreat-from-last-weeks-highs.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1197656800","content_text":"KEY POINTSInvestors on Tuesday will be keeping a close watch on comments made by both Securities and Exchange Commission Chair nominee Gary Gensler and Federal Reserve Governor Lael Brainard.Gensler will testify before the Senate Banking Committee at 10 a.m. ET.Brainard will then deliver a speech entitled \"U.S. Economic Outlook and Monetary Policy\" via a virtual meeting hosted by the Council on Foreign Relations, at 1 p.m. ET.U.S. Treasury yields fell on Tuesday morning, with investors expected to be watching for comments on the economy in key speeches later in the day.The yield on the benchmark10-year Treasury notefell to 1.426% at 3:50 a.m. ET. The yield on the30-year Treasury bonddipped to 2.206%. Yields move inversely to prices.Treasury yields ebbed lower, with the 10-year continuing to fall back from last week's highs, when it topped 1.6%.Investors on Tuesday will be keeping a close watch oncommentsmade by both Securities and Exchange Commission Chair nominee Gary Gensler and Federal Reserve Governor Lael Brainard.Gensler will testify before the Senate Banking Committee at 10 a.m. ET.Brainard will then deliver a speech entitled \"U.S. Economic Outlook and Monetary Policy\" via a virtual meeting hosted by the Council on Foreign Relations, at 1 p.m. ET.March data from the IBD/TIPP Economic Optimism index is due out at 10 a.m. ET.An auction will be held Tuesday for $30 billion of 42-day bills.","news_type":1},"isVote":1,"tweetType":1,"viewCount":233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":365079319,"gmtCreate":1614684700231,"gmtModify":1704773978946,"author":{"id":"3572419380684882","authorId":"3572419380684882","name":"Joyce_c","avatar":"https://static.tigerbbs.com/faf0f288ddf8de4ed8f2127882064d27","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572419380684882","authorIdStr":"3572419380684882"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/365079319","repostId":"1198289081","repostType":4,"repost":{"id":"1198289081","pubTimestamp":1614676006,"share":"https://ttm.financial/m/news/1198289081?lang=&edition=fundamental","pubTime":"2021-03-02 17:06","market":"us","language":"en","title":"Beyond Meat Prepares for a High-Growth Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=1198289081","media":"zacks","summary":"I’ve been a Beyond Meat (BYND) fan for a while now, despite the crazy way the pandemic has moved its","content":"<p>I’ve been a Beyond Meat (BYND) fan for a while now, despite the crazy way the pandemic has moved its shares around. Somehow, I really like the sound of “revolutionary plant-based meats made from simple ingredients without GMOs, bioengineered ingredients, hormones, antibiotics, or cholesterol.”</p><p>Everyone may not care for a meat substitute when they can have the real thing. But my feeling is that more and more people will have it at least sometimes, as a token to the environment, or out of animal love, or for health reasons. And when they do that, they might consider an offering from a popular brand name. Especially when it’s so easily available at the friendly neighborhood McDonalds (MCD Quick QuoteMCD-Free Report) . Or a KFC, or a Pizza Hut or, or a Taco Bell for that matter.</p><p>So it’s important to remember that we are in unusual times. And unusual things happen in unusual times.</p><p>And if that means that a company like Beyond Meat has to offer discounts, write off some inventory, or absorb extra costs, so be it. After all, nobody could have planned for a health crisis coming along and shutting down all the restaurants and sending people indoors for protection.</p><p>As investors, we should be thinking longer-term.</p><p>That means we should be looking at the long-term potential for revenue and earnings growth despite the near-term challenges.</p><p>Let’s take revenue first. In the just-reported quarter, the company managed to grow sales just 3.5% from the year-ago period, as softness at foodservice offset tremendous growth at retail (both in the U.S and international markets).</p><p>People generally buy familiar brands at grocery stores. So the surge in sales indicates strong underlying demand and growing brand awareness.</p><p>Okay, so it’s offering discounts. But so is prime competitor Impossible Foods. There’s something of a pricing war going on there with Impossible being the more aggressive. Management commentary also indicates that the absorption of higher fixed cost from operating below capacity in the prior quarter was a bigger driver of weakness.</p><p>The company is also adding IT infrastructure, it’s also adding headcount in an effort to boost R&amp;D and marketing and support international expansion in Europe and China. It’s also adding production capacity in these two international markets.</p><p>So while on the one hand we are seeing it building its own brand and internal capabilities, on the other, it is signing long-term deals with leading brands like McDonalds, Yum Brands (YUM Quick QuoteYUM-Free Report) and Pepsico (PEP Quick QuotePEP-Free Report) . When you’re mainly selling into mom n pops, business can be more uncertain. But when you’re selling into recognized leaders in foodservice with deeper pockets to withstand near-term issues, and also testing the water in healthy snacks, the business will obviously be more stable.</p><p>But all this wouldn’t be as good if Beyond Meat wasn’t a great innovator. And it has made great strides in this. It has moved on from its burger patty to create sausage and meatballs. Its agreement with McDonalds includes a promise of co-developed plant-based chicken, pork and eggs. Its agreement with Yum includes the creation of signature menu items in different plant-based categories.</p><p>Zacks Estimates currently expect the company to swing to a profit this year while growing revenues 53.8%. Both these numbers are due for a revision given the new deals and expected increase in costs (the commencement of production at international facilities should have a mitigating effect on cost and reduce logistics complications).</p><p>While trading below their median value over the past year, Beyond Meat shares aren’t cheap. So we could wait for a better entry point.</p><p><img src=\"https://static.tigerbbs.com/8d24f3c0541515034c6c9e016a8cabe3\" tg-width=\"620\" tg-height=\"261\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beyond Meat Prepares for a High-Growth Phase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeyond Meat Prepares for a High-Growth Phase\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-02 17:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zacks.com/stock/news/1270468/beyond-meat-prepares-for-a-high-growth-phase?art_rec=home-home-investment_ideas_stocks-ID12-txt-1129470><strong>zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I’ve been a Beyond Meat (BYND) fan for a while now, despite the crazy way the pandemic has moved its shares around. Somehow, I really like the sound of “revolutionary plant-based meats made from ...</p>\n\n<a href=\"https://www.zacks.com/stock/news/1270468/beyond-meat-prepares-for-a-high-growth-phase?art_rec=home-home-investment_ideas_stocks-ID12-txt-1129470\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc."},"source_url":"https://www.zacks.com/stock/news/1270468/beyond-meat-prepares-for-a-high-growth-phase?art_rec=home-home-investment_ideas_stocks-ID12-txt-1129470","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198289081","content_text":"I’ve been a Beyond Meat (BYND) fan for a while now, despite the crazy way the pandemic has moved its shares around. Somehow, I really like the sound of “revolutionary plant-based meats made from simple ingredients without GMOs, bioengineered ingredients, hormones, antibiotics, or cholesterol.”Everyone may not care for a meat substitute when they can have the real thing. But my feeling is that more and more people will have it at least sometimes, as a token to the environment, or out of animal love, or for health reasons. And when they do that, they might consider an offering from a popular brand name. Especially when it’s so easily available at the friendly neighborhood McDonalds (MCD Quick QuoteMCD-Free Report) . Or a KFC, or a Pizza Hut or, or a Taco Bell for that matter.So it’s important to remember that we are in unusual times. And unusual things happen in unusual times.And if that means that a company like Beyond Meat has to offer discounts, write off some inventory, or absorb extra costs, so be it. After all, nobody could have planned for a health crisis coming along and shutting down all the restaurants and sending people indoors for protection.As investors, we should be thinking longer-term.That means we should be looking at the long-term potential for revenue and earnings growth despite the near-term challenges.Let’s take revenue first. In the just-reported quarter, the company managed to grow sales just 3.5% from the year-ago period, as softness at foodservice offset tremendous growth at retail (both in the U.S and international markets).People generally buy familiar brands at grocery stores. So the surge in sales indicates strong underlying demand and growing brand awareness.Okay, so it’s offering discounts. But so is prime competitor Impossible Foods. There’s something of a pricing war going on there with Impossible being the more aggressive. Management commentary also indicates that the absorption of higher fixed cost from operating below capacity in the prior quarter was a bigger driver of weakness.The company is also adding IT infrastructure, it’s also adding headcount in an effort to boost R&D and marketing and support international expansion in Europe and China. It’s also adding production capacity in these two international markets.So while on the one hand we are seeing it building its own brand and internal capabilities, on the other, it is signing long-term deals with leading brands like McDonalds, Yum Brands (YUM Quick QuoteYUM-Free Report) and Pepsico (PEP Quick QuotePEP-Free Report) . When you’re mainly selling into mom n pops, business can be more uncertain. But when you’re selling into recognized leaders in foodservice with deeper pockets to withstand near-term issues, and also testing the water in healthy snacks, the business will obviously be more stable.But all this wouldn’t be as good if Beyond Meat wasn’t a great innovator. And it has made great strides in this. It has moved on from its burger patty to create sausage and meatballs. Its agreement with McDonalds includes a promise of co-developed plant-based chicken, pork and eggs. Its agreement with Yum includes the creation of signature menu items in different plant-based categories.Zacks Estimates currently expect the company to swing to a profit this year while growing revenues 53.8%. Both these numbers are due for a revision given the new deals and expected increase in costs (the commencement of production at international facilities should have a mitigating effect on cost and reduce logistics complications).While trading below their median value over the past year, Beyond Meat shares aren’t cheap. So we could wait for a better entry point.","news_type":1},"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":365070367,"gmtCreate":1614684610559,"gmtModify":1704773977655,"author":{"id":"3572419380684882","authorId":"3572419380684882","name":"Joyce_c","avatar":"https://static.tigerbbs.com/faf0f288ddf8de4ed8f2127882064d27","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572419380684882","authorIdStr":"3572419380684882"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/365070367","repostId":"2116656568","repostType":4,"isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":366470677,"gmtCreate":1614558350199,"gmtModify":1704772375510,"author":{"id":"3572419380684882","authorId":"3572419380684882","name":"Joyce_c","avatar":"https://static.tigerbbs.com/faf0f288ddf8de4ed8f2127882064d27","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572419380684882","authorIdStr":"3572419380684882"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZOM\">$Zomedica Pharmaceuticals Corp.(ZOM)$</a>good?","listText":"<a href=\"https://laohu8.com/S/ZOM\">$Zomedica Pharmaceuticals Corp.(ZOM)$</a>good?","text":"$Zomedica Pharmaceuticals Corp.(ZOM)$good?","images":[{"img":"https://static.tigerbbs.com/270972e4680428742e5f7889c4aad4ca","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/366470677","isVote":1,"tweetType":1,"viewCount":98,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}